Biggest changeIFP Plans 2024 compared to 2023 – Total acquisition cost per IFP-equivalent approved member increased $126, or 53% driven by: • a $77, or 43%, increase in CC&E cost per IFP-equivalent due to the overall decline in individual and family plan and short-term plan approved members as well as a higher number of benefit advisors than in the same period last year, and • a $49, or 80%, increase in variable marketing cost per IFP-equivalent approved member, primarily due to unfavorable channel mix. 56 Table of Contents Results of Operations The following table sets forth our operating results and related percentage of total revenue for the years presented below (dollars in thousands): Year Ended December 31, 2024 2023 Revenue: Commission $ 461,647 87 % $ 403,924 89 % Other 70,763 13 % 48,947 11 % Total revenue 532,410 100 % 452,871 100 % Operating costs and expenses (1) Cost of revenue 1,794 — % 1,771 — % Marketing and advertising 190,837 36 % 172,640 38 % Customer care and enrollment 163,448 31 % 149,562 33 % Technology and content 53,520 10 % 58,609 13 % General and administrative 89,765 17 % 99,363 22 % Impairment, restructuring and other charges 9,475 2 % — — % Total operating costs and expenses 508,839 96 % 481,945 106 % Income (loss) from operations 23,571 4 % (29,074) (6) % Interest expense (11,159) (2) % (10,974) (2) % Other income, net 6,900 1 % 9,453 2 % Income (loss) before income taxes 19,312 4 % (30,595) (7) % Benefit from (provision for) income taxes 9,255 2 % (2,381) (1) % Net income (loss) $ 10,057 2 % $ (28,214) (6) % ____________ (1) Operating costs and expenses include the following amounts of stock-based compensation expense (in thousands): Year Ended December 31, 2024 2023 Marketing and advertising $ 2,413 $ 2,201 Customer care and enrollment 1,845 2,287 Technology and content 3,331 4,498 General and administrative 12,292 14,227 Total stock-based compensation expense $ 19,881 $ 23,213 Revenue Our commission revenue, other revenue and total revenue are summarized as follows (dollars in thousands): Change 2024 2023 $ % Commission $ 461,647 $ 403,924 $ 57,723 14 % % of total revenue 87 % 89 % Other 70,763 48,947 21,816 45 % % of total revenue 13 % 11 % Total revenue $ 532,410 $ 452,871 $ 79,539 18 % 57 Table of Contents 2024 compared to 2023 – Commission revenue increased $57.7 million, or 14%, in 2024 compared to 2023 due to: • a $71.9 million, or 20%, increase in commission revenue from the Medicare segment driven by: ◦ a 26% increase in Medicare Advantage plan approved members, ◦ improved constrained LTV of commissions per approved member for Medicare Advantage and Medicare Supplement plans, ◦ partially offset by lower net adjustment revenue from prior period enrollments, which was $18.7 million in 2024 compared to $33.5 million in 2023, and ◦ decreases in approved membership for both Medicare Supplement and Medicare Part D plans. • a $14.2 million, or 32%, decrease in commission revenue from the E&I segment primarily driven by: ◦ lower net adjustment revenue from prior period enrollments, which was $4.1 million in 2024 compared to $14.5 million in 2023, ◦ a 24%, 9% and 30% decrease in individual and family plan, ancillary product and small business approved members, respectively, ◦ partially offset by a 17% and 14% improvement in constrained LTV of commissions per approved member for dental and vision plans, respectively.
Biggest changeIFP Plans 2025 compared to 2024 – Total acquisition cost per IFP-equivalent approved member increased $50, or 14%, driven by a $19, or 7%, increase in CC&E cost per IFP-equivalent and a $31, or 28%, increase in variable marketing cost per IFP-equivalent approved member, primarily driven by the overall decline in individual and family plan and short-term plan approved members. 50 Table of Contents Results of Operations The following table sets forth our operating results and related percentage of total revenue for the years presented below (dollars in thousands): Year Ended December 31, 2025 2024 Revenue: Commission $ 497,955 90 % $ 461,647 87 % Other 56,053 10 % 70,763 13 % Total revenue 554,008 100 % 532,410 100 % Operating costs and expenses (1) Marketing and advertising 181,240 33 % 192,631 36 % Customer care and enrollment 162,885 29 % 163,448 31 % Technology and content 51,829 9 % 53,520 10 % General and administrative 89,555 16 % 89,765 17 % Impairment, restructuring and other charges 2,010 — % 9,475 2 % Total operating costs and expenses 487,519 88 % 508,839 96 % Income from operations 66,489 12 % 23,571 4 % Interest expense (10,761) (2) % (11,159) (2) % Other income, net 2,998 1 % 6,900 1 % Income before income taxes 58,726 11 % 19,312 4 % Provision for income taxes 18,682 3 % 9,255 2 % Net income $ 40,044 7 % $ 10,057 2 % ____________ (1) Operating costs and expenses include the following amounts of stock-based compensation expense (in thousands): Year Ended December 31, 2025 2024 Marketing and advertising $ 2,268 $ 2,413 Customer care and enrollment 1,221 1,845 Technology and content 2,552 3,331 General and administrative 9,002 12,292 Total stock-based compensation expense $ 15,043 $ 19,881 Revenue Our commission revenue, other revenue and total revenue are summarized as follows (dollars in thousands): Change 2025 2024 $ % Commission $ 497,955 $ 461,647 $ 36,308 8 % % of total revenue 90 % 87 % Other 56,053 70,763 (14,710) (21) % % of total revenue 10 % 13 % Total revenue $ 554,008 $ 532,410 $ 21,598 4 % 51 Table of Contents 2025 compared to 2024 – Commission revenue increased $36.3 million, or 8%, in 2025 compared to 2024 due to: • a $44.6 million, or 10%, increase in commission revenue from the Medicare segment driven by: ◦ higher net adjustment revenue from prior period enrollments, which was $43.0 million in 2025 compared to $18.7 million in 2024, ◦ improved constrained LTV of commissions per approved member for all Medicare products, ◦ a significant increase in hospital indemnity plan approved members, and ◦ partially offset by a 7% decrease in Medicare plan approved members. • a $8.3 million, or 28%, decrease in commission revenue from the E&I segment primarily driven by: ◦ a 25% and 35% decrease in individual and family plan and short-term health plan approved members, respectively, along with lower constrained LTV of commissions for these products, ◦ lower net adjustment revenue from prior period enrollments, which was $1.4 million in 2025 compared to $4.1 million in 2024, and ◦ partially offset by a 5%, 1% and 9% improvement in constrained LTV of commissions per approved member for dental, vision and small business plans, respectively.
Seasonality See Item 1 , Business – Seasonality, for information regarding seasonal impacts on our business and financial condition and results of operations. Critical Accounting Estimates The preparation of financial statements and related disclosures in conformity with U.S. generally accepted accounting principles (“U.S.
Seasonality See Item 1 , Business, for information regarding seasonal impacts on our business and financial condition and results of operations. Critical Accounting Estimates The preparation of financial statements and related disclosures in conformity with U.S. generally accepted accounting principles (“U.S.
Our commissions may include certain bonus payments, which are generally based on attaining predetermined target sales levels or other objectives, as determined by the health insurance carriers.
Our commissions may also include certain bonus payments, which are generally based on attaining predetermined target sales levels or other objectives, as determined by the health insurance carriers.
Through December 31, 2024, we had not declared or paid any cash dividends to common stockholders, and we do not expect to pay any in the foreseeable future. We base the risk-free interest rate on the implied yield currently available on U.S. Treasury zero-coupon issues with a remaining term equal to the expected term of our stock options.
Through December 31, 2025, we had not declared or paid any cash dividends to common stockholders, and we do not expect to pay any in the foreseeable future. We base the risk-free interest rate on the implied yield currently available on U.S. Treasury zero-coupon issues with a remaining term equal to the expected term of our stock options.
Segment gross profit (loss) is calculated as total revenue for the applicable segment less variable marketing and advertising, segment CC&E and cost of revenue for the applicable segment.
Segment gross profit (loss) is calculated as total revenue for the applicable segment less variable marketing and advertising expenses, segment CC&E expenses and cost of revenue for the applicable segment.
The Medicare segment consists primarily of commissions earned as the broker of record from our sale of Medicare-related health insurance plans, including Medicare Advantage, Medicare Supplement and Medicare Part D prescription drug plans, and to a lesser extent, ancillary products sold to our Medicare-eligible beneficiaries, including but not limited to, dental and vision plans.
The Medicare segment consists primarily of commissions earned as the broker of record from our sale of Medicare-related health insurance plans, including Medicare Advantage, Medicare Supplement and Medicare Part D prescription drug plans, and to a lesser extent, ancillary products sold to our Medicare-eligible beneficiaries, including but not limited to, dental and vision insurance and hospital indemnity plans.
Overview We are a leading private health insurance marketplace with a technology and service platform that provides consumer engagement, education, and health insurance enrollment solutions. Our mission is to expertly guide consumers through their health insurance enrollment and related options, when, where, and how they prefer.
Overview We are a leading private health insurance marketplace with a technology and service platform that provides consumer engagement, education, and health insurance enrollment solutions. Our mission is to expertly guide consumers, or beneficiaries, through their health insurance enrollment and related options, when, where, and how they prefer.
Investment Agreement, for as long as H.I.G. continues to own at least 30% of the Series A Preferred Stock originally issued to it in the private placement, entitles H.I.G., subject to the conditions and restrictions specified therein, to additional rights, including the right to nominate one additional member to the Company’s Board of Directors, the right to approve the Company’s annual budget, the right to approve hiring or termination of certain key executives and the right to approve the incurrence of certain indebtedness.
Investment Agreement, for as long as H.I.G. continues to own at least 30% of the Series A Preferred Stock originally issued to it in the private placement, entitles H.I.G., subject to the conditions and restrictions specified therein, to additional rights, including the right to nominate one additional member to the Company’s Board of Directors, the right to approve the Company’s annual budget, the right to 59 Table of Contents approve hiring or termination of certain key executives and the right to approve the incurrence of certain indebtedness.
We also maintained $3.1 million in restricted cash as of December 31, 2024 and 2023. Material Cash Requirements Our material cash requirements include our operating leases and service and licensing obligations. See Note 10 – Leases in our Notes to Consolidated Financial Statements for details of our operating lease obligations.
We also maintained $3.1 million in restricted cash as of December 31, 2025 and 2024. Material Cash Requirements Our material cash requirements include our operating leases and service and licensing obligations. See Note 10 – Leases in our Notes to Consolidated Financial Statements for details of our operating lease obligations.
The non-compliance with the Minimum Asset Coverage Ratio or the Minimum Liquidity Amount does not entitle H.I.G. to accelerate the redemption of the 65 Table of Contents Series A Preferred Stock nor is it expected to materially impact our ability to generate and obtain adequate amounts of cash to meet our short-term or long-term requirements.
The non-compliance with the Minimum Asset Coverage Ratio or the Minimum Liquidity Amount does not entitle H.I.G. to accelerate the redemption of the Series A Preferred Stock nor is it expected to materially impact our ability to generate and obtain adequate amounts of cash to meet our short-term or long-term requirements.
Our omnichannel consumer engagement platform differentiates our offering from competitors and enables consumers to use our services online, by telephone with a licensed insurance agent, or benefit advisor, or through a hybrid online assisted interaction that includes live agent chat and co-browsing capabilities.
Our omnichannel consumer engagement platform differentiates our offering from competitors and enables consumers to use our services through our self-service online platform, by telephone with a licensed and trained insurance agent, or benefit advisor, or through a hybrid online assisted interaction that includes live agent chat and co-browsing capabilities.
We have created a consumer-centric marketplace that offers consumers a broad choice of insurance products that includes thousands of Medicare Advantage, Medicare Supplement, Medicare Part D prescription drug, individual, family, small business and other ancillary health insurance products from over 180 health insurance carriers nationwide.
We have created a consumer-centric marketplace that offers consumers a broad choice of insurance products that includes thousands of Medicare Advantage, Medicare Supplement, Medicare Part D prescription drug, individual, family, small business and other ancillary health insurance products from over 180 health insurance carriers nationwide, including approximately 50 Medicare health insurance carriers.
To the extent we determine through confirmations from a health insurance carrier that a commission payment is delayed 54 Table of Contents or is inaccurate as of the date of estimation, we adjust the estimated membership to also reflect the number of members for whom we expect to receive or to refund a commission payment.
To the extent we determine through confirmations from a health insurance carrier that a commission payment is delayed or is inaccurate as of the date of estimation, we adjust the estimated membership to also reflect the number of members for whom we expect to receive or to refund a commission payment.
See Note 6 – Convertible Preferred Stock in our Notes to Consolidated Financial Statements for information regarding our preferred stock transaction in 2021 . We also had $3.1 million and $3.1 million in restricted cash as of December 31, 2024 and 2023, respectively.
See Note 6 – Convertible Preferred Stock in our Notes to Consolidated Financial Statements for information regarding our preferred stock transaction in 2021 . We also had $3.1 million in restricted cash as of December 31, 2025 and 2024.
The E&I segment consists primarily of commissions earned from our sale of individual and family plans, including both qualified and non-qualified, small business health insurance plans and ancillary products sold to our non-Medicare-eligible consumers, including but not limited to, dental, vision and short-term insurance.
The E&I segment consists primarily of commissions earned from our sale of individual and family plans, including both qualified and non-qualified plans, employer plans, which include small business health insurance plans and ICHRAs, and ancillary products sold to our non-Medicare-eligible consumers, including but not limited to, dental, vision and short-term insurance.
As of December 31, 2024 and 2023, we had a total of 13.4 million and 12.8 million shares held in treasury stock, respectively. This included 2.7 million and 2.1 million shares, respectively, as of December 31, 2024 and 2023 that were repurchased to satisfy tax withholding obligations and 10.7 million shares previously repurchased as of December 31, 2024 and 2023.
As of December 31, 2025 and 2024, we had a total of 13.8 million and 13.4 million shares held in treasury stock, respectively. This included 3.1 million and 2.7 million shares, respectively, as of December 31, 2025 and 2024 that were repurchased to satisfy tax withholding obligations and 10.7 million shares previously repurchased as of December 31, 2025 and 2024.
Cash used from changes in net operating assets and liabilities during 2024 primarily consisted of increases of $81.9 million in contract assets – commissions receivable, $12.8 million in accounts receivable and $4.2 million in prepaid expenses, partially offset by a decrease of $16.2 million in accounts payable.
Cash used from changes in net operating assets and liabilities during 2024 primarily consisted of increases of $81.9 million in contract assets – commissions receivable, $12.8 million in accounts receivable and $4.2 million in prepaid expenses, partially offset by an increase of $16.2 million in accounts payable.
We recognize positive adjustments to revenue to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. See Segment Information below and Note 2 – Revenue in our Notes to Consolidated Financial Statements for more information on commission revenue.
We recognize positive adjustments to revenue to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. See Segment Information below and Note 1 – Summary of Business and Significant Accounting Policies and Note 2 – Revenue in our Notes to Consolidated Financial Statements for more information on commission revenue.
Stock-Based Compensation We recognize stock-based compensation expense in the accompanying Consolidated Statements of Comprehensive Income (Loss) ratably based on the fair value of our stock-based awards over their respective requisite service periods, typically the vesting period, which is generally three to four years for service-based awards for employees and one year for outside directors or the one-year anniversary of achieving performance criteria for performance-based awards.
Stock-Based Compensation We recognize stock-based compensation expense in the accompanying Consolidated Statements of Comprehensive Income ratably based on the fair value of our stock-based awards over their respective requisite service periods, typically the vesting period, which is generally three to four years for service-based awards for employees and one year for outside directors.
In 2023, the effective tax rate was lower than the statutory tax rate due to stock-based compensation adjustments and changes to the valuation allowance, offset by state tax and research and development tax credits. 61 Table of Contents Segment Information We report segment information based on how our chief executive officer, who is our chief operating decision maker (“CODM”), regularly reviews our operating results, allocates resources, and makes decisions regarding our business operations in the annual budget and forecasting process along with evaluation of actual performance.
In 2024, the effective tax rate was higher than the statutory tax rate due to stock-based compensation adjustments and state taxes, offset by research and development tax credits. 55 Table of Contents Segment Information We report segment information based on how our chief executive officer, who is our chief operating decision maker (“CODM”), regularly reviews our operating results, allocates resources, and makes decisions regarding our business operations in the annual budget and forecasting process along with evaluation of actual performance.
We recognize expenses in our direct marketing acquisition channel in the period in which they are incurred, including in the period in which the consumer clicks on the advertisement for 58 Table of Contents direct online channels.
We recognize direct marketing expenses in our direct marketing acquisition channel in the period in which they are incurred, including in the period in which the consumer clicks on the advertisement for direct online channels.
Our impairment, restructuring and other charges are summarized as follows (dollars in thousands): Change 2024 2023 $ % Impairment, restructuring and other charges $ 9,475 $ — $ 9,475 * % of total revenue 2 % — % ______________ * Percentage calculated is not meaningful. 2024 compared to 2023 – We incurred $9.5 million in impairment, restructuring and other charges for the year ended December 31, 2024 compared to no impairment, restructuring and other charges for the same period in 2023.
Our impairment, restructuring and other charges are summarized as follows (dollars in thousands): Change 2025 2024 $ % Impairment, restructuring and other charges $ 2,010 $ 9,475 $ (7,465) (79) % % of total revenue — % 2 % ______________ * Percentage calculated is not meaningful. 2025 compared to 2024 – We incurred $2.0 million in impairment, restructuring and other charges for the year ended December 31, 2025 compared to $9.5 million for the same period in 2024.
Our principal uses of cash in recent periods have been funding working capital, purchases of short-term investments, the satisfaction of tax withholding obligations in connection with the settlement of restricted stock units, making payments on our operating lease obligations and service and licensing obligations and complying with our debt servicing requirements and preferred stock dividend payment obligations. 64 Table of Contents Cash and Cash Equivalents Our cash, cash equivalents, and short-term marketable securities are summarized as follows (in thousands): December 31, 2024 December 31, 2023 Cash and cash equivalents $ 39,197 $ 115,722 Short-term marketable securities 43,043 5,930 Total cash, cash equivalents, and short-term marketable securities $ 82,240 $ 121,652 Cash equivalents, which are comprised of financial instruments with an original maturity of 90 days or less from the date of purchase, primarily consist of commercial paper, money market funds and agency bonds.
Our principal uses of cash in recent periods have been funding working capital, purchases of short-term investments, the satisfaction of tax withholding obligations in connection with the settlement of restricted stock units, making payments on our operating lease obligations and service and licensing obligations and complying with our debt servicing requirements and preferred stock dividend payment obligations. 58 Table of Contents Cash and Cash Equivalents Our cash, cash equivalents, and short-term marketable securities are summarized as follows (in thousands): December 31, 2025 December 31, 2024 Cash and cash equivalents $ 73,725 $ 39,197 Short-term marketable securities 3,495 43,043 Total cash, cash equivalents, and short-term marketable securities $ 77,220 $ 82,240 Cash equivalents, which are comprised of financial instruments with an original maturity of 90 days or less from the date of purchase, primarily consist of commercial paper, money market funds and government securities.
Impairment, Restructuring and Other Charges Our impairment, restructuring and other charges consist primarily of severance, transition and other related costs and goodwill and intangible asset impairment charges.
Impairment, Restructuring and Other Charges Our impairment, restructuring and other charges consist primarily of severance, transition and other related costs and impairment charges.
The charges consisted of $7.5 million of impairment related to several of our leased office spaces, which included $7.0 million of operating lease right-of-use asset impairments and $0.5 million of property and equipment impairments.
The charges in 2024 consisted of $7.5 million of impairment related to several of our leased office spaces, specifically consisting of $7.0 million of operating lease right-of-use asset impairments and $0.5 million of property and equipment impairments.
Our commission revenue is influenced by a number of factors including but not limited to: • the number of individuals on applications for Medicare-related, individual and family, small business and ancillary health insurance plans that are approved by the relevant health insurance carriers; 51 Table of Contents • the number of approved members for Medicare-related, individual and family, small business and ancillary health insurance plans from whom we have received an initial commission payment; and • the constrained lifetime value (“LTV”) of approved members for Medicare-related, individual and family and ancillary health insurance plans we sell, as well as the estimated annual value of approved members for small business plans we sell.
Our commission revenue is influenced by a number of factors including but not limited to: • the number of individuals on applications for Medicare-related, individual and family, small business and ancillary health insurance plans that are approved by the relevant health insurance carriers; • the number of approved members for Medicare-related, individual and family, small business and ancillary health insurance plans from whom we have received an initial commission payment; and • the constrained lifetime value (“LTV”) of approved members for Medicare-related, individual and family and ancillary health insurance plans we sell, as well as the estimated annual value of approved members for small business plans we sell. 45 Table of Contents Approved Members Approved members represent the number of individuals on submitted applications, or submissions, which were approved by the relevant insurance carrier for the identified product during the current period.
Cash Activities Our cash flows for the years ended December 31, 2024 and 2023 are summarized as follows (in thousands): Year Ended December 31, 2024 2023 Net cash used in operating activities $ (18,366) $ (6,692) Net cash used in investing activities (48,421) (15,893) Net cash used in financing activities (9,674) (6,224) 66 Table of Contents Operating Activities Net cash used in operating activities primarily consists of net income (loss), adjusted for certain non-cash items, including deferred income taxes, stock-based compensation expense, depreciation and amortization, amortization of intangible assets and internally developed software, other non-cash items, and the effect of changes in working capital and other activities.
Cash Activities Our cash flows for the years ended December 31, 2025 and 2024 are summarized as follows (in thousands): Year Ended December 31, 2025 2024 Net cash used in operating activities $ (25,345) $ (18,366) Net cash provided by (used in) investing activities 25,432 (48,421) Net cash provided by (used in) financing activities 34,288 (9,674) 61 Table of Contents Operating Activities Net cash used in operating activities primarily consists of net income (loss), adjusted for certain non-cash items, including deferred income taxes, stock-based compensation expense, depreciation and amortization, amortization of intangible assets and internally developed software, other non-cash items, and the effect of changes in working capital and other activities.
The numerator used to calculate each member acquisition metric discussed above is the portion of the respective operating expenses for CC&E and marketing and advertising that is directly related to member acquisition for our sale of Medicare Advantage, Medicare Supplement and Medicare Part D prescription drug plans (collectively, “Medicare Plans”) and for all individual and family major medical plans and short-term health insurance plans (collectively, “IFP Plans”), respectively, for which we are the broker of record.
Variable marketing costs exclude fixed overhead costs, such as personnel related costs, consulting expenses, and other operating costs allocated to the marketing and advertising department. 49 Table of Contents The numerator used to calculate each member acquisition metric discussed above is the portion of the respective operating expenses for CC&E and marketing and advertising that is directly related to member acquisition for our sale of Medicare Advantage, Medicare Supplement and Medicare Part D prescription drug plans (collectively, “Medicare Plans”) and for all individual and family major medical plans and short-term health insurance plans (collectively, “IFP Plans”), respectively, for which we are the broker of record.
Short-term obligations were $9.2 million for leases and $8.2 million for service and licensing as of December 31, 2024. Long-term obligations were $22.8 million for leases and $4.8 million for service and licensing as of December 31, 2024. We expect to fund these obligations through our existing cash and cash equivalents and cash generated from operations.
Short-term obligations were $8.4 million for leases and $10.6 million for service and licensing as of December 31, 2025. Long-term obligations were $15.2 million for leases and $3.5 million for service and licensing as of December 31, 2025. We expect to fund these obligations through our existing cash and cash equivalents and cash generated from operations.
Investment Agreement and the term loan we obtained on February 28, 2022 under the Credit Agreement, and expected cash collections will be sufficient to fund our operations for at least 12 months after the filing date of this Annual Report on Form 10-K.
Investment Agreement and the proceeds we obtained on December 31, 2025 under the Revolving Credit Agreement, and expected cash collections will be sufficient to fund our operations for at least 12 months after the filing date of this Annual Report on Form 10-K.
We provide annual services in selling and renewing small business health insurance plans; therefore, we recognize small business health insurance plan commission revenue at the time the plan is approved by the carrier, and when it renews each year thereafter, equal to the estimated commissions we expect to collect from the plan over the following 12 months.
For small business plans, we recognize commission revenue at the time the plan is approved by the carrier, and when it renews each year thereafter, equal to the estimated commissions we expect to collect from the plan over the following 12 months.
Investment Agreement”), we issued and sold 2,250,000 shares of Series A convertible preferred stock (“Series A Preferred Stock”) at an aggregate purchase price of $225.0 million to H.I.G. in a private placement and received $214.0 million net proceeds on April 30, 2021. During the year ended December 31, 2024, we paid cash dividends in the aggregate amount of $5.6 million.
Investment Agreement”), we issued and sold 2,250,000 shares of Series A convertible preferred stock (“Series A Preferred Stock”) at an aggregate purchase price of $225.0 million to H.I.G. in a private placement and received $214.0 million net proceeds on April 30, 2021.
In 2024, the effective tax rate was higher than the statutory tax rate due to stock-based compensation adjustments and state tax, offset by research and development tax credits. Year Ended December 31, 2023 – For the year ended December 31, 2023, we recorded a benefit from income taxes of $2.4 million representing an effective tax rate of 7.8%.
In 2025, the effective tax rate was higher than the statutory tax rate due to state taxes and stock-based compensation adjustments, offset by research and development tax credits. Year Ended December 31, 2024 – For the year ended December 31, 2024, we recorded a provision for income taxes of $9.3 million representing an effective tax rate of 47.9%.
Year Ended December 31, 2023 – Net cash used in financing activities of $6.2 million during 2023 was primarily attributable to $3.5 million of preferred stock cash dividends and $3.3 million of cash used for share repurchases to satisfy employee tax withholding obligations.
Year Ended December 31, 2024 – Net cash used in financing activities of $9.7 million during 2024 was primarily attributable to $5.6 million of preferred stock cash dividends, $3.4 million of cash used for share repurchases to satisfy employee tax withholding obligations and $1.1 million for payment of debt issuance costs.
Given the number of months required to observe non-payment of commissions in order to confirm cancellations, we estimate the number of members who are active on insurance policies as of a specified date.
Given the number of months required to observe non-payment of commissions in order to confirm cancellations, especially as some of our members pay their premiums less frequently than monthly, we estimate the number of members who are active on insurance policies as of a specified date.
Year Ended December 31, 2024 – Net cash used in investing activities of $48.4 million during 2024 mainly consisted of $97.0 million used to purchase marketable securities and $10.8 million of capitalized internal-use software and website development costs, partially offset by $61.4 million of proceeds from redemption and maturities of marketable securities.
Year Ended December 31, 2025 – Net cash provided by investing activities of $25.4 million during 2025 mainly consisted of $114.8 million of proceeds from redemption and maturities of marketable securities, partially offset by $74.0 million used to purchase marketable securities and $13.1 million of capitalized internal-use software and website development costs.
Provision for (Benefit from) Income Taxes Our provision for (benefit from) income taxes is summarized as follows (dollars in thousands): Change 2024 2023 $ % Provision for (benefit from) income taxes $ 9,255 $ (2,381) $ 11,636 (489) % Effective tax rate 47.9 % 7.8 % Year Ended December 31, 2024 – For the year ended December 31, 2024, we recorded a provision for income taxes of $9.3 million representing an effective tax rate of 47.9%.
Provision for Income Taxes Our provision for income taxes is summarized as follows (dollars in thousands): Change 2025 2024 $ % Provision for income taxes $ 18,682 $ 9,255 $ 9,427 102 % Effective tax rate 31.8 % 47.9 % Year Ended December 31, 2025 – For the year ended December 31, 2025, we recorded a provision for income taxes of $18.7 million representing an effective tax rate of 31.8%.
Our other income, net is summarized as follows (dollars in thousands): Change 2024 2023 $ % Other income, net $ 6,900 $ 9,453 $ (2,553) (27) % % of total revenue 1 % 2 % 2024 compared to 2023 – Other income, net was $6.9 million in 2024 compared to other income, net of $9.5 million in 2023.
Our other income, net is summarized as follows (dollars in thousands): Change 2025 2024 $ % Other income, net $ 2,998 $ 6,900 $ (3,902) (57) % % of total revenue 1 % 1 % 2025 compared to 2024 – Other income, net was $3.0 million in 2025 compared to other income, net of $6.9 million in 2024.
Year Ended December 31, 2023 – Net cash used in investing activities of $15.9 million during 2023 mainly consisted of $54.5 million used to purchase marketable securities and $8.7 million of capitalized internal-use software and website development costs, partially offset by $49.4 million of proceeds from redemption and maturities of marketable securities. 67 Table of Contents Financing Activities Year Ended December 31, 2024 – Net cash used in financing activities of $9.7 million during 2024 was primarily attributable to $5.6 million of preferred stock cash dividends, $3.4 million of cash used for share repurchases to satisfy employee tax withholding obligations and $1.1 million for payment of debt issuance costs.
Year Ended December 31, 2024 – Net cash used in investing activities of $48.4 million during 2024 mainly consisted of $97.0 million used to purchase marketable securities and $10.8 million of capitalized internal-use software and website development costs, partially offset by $61.4 million of proceeds from redemption and maturities of marketable securities. 62 Table of Contents Financing Activities Year Ended December 31, 2025 – Net cash provided by financing activities of $34.3 million during 2025 was primarily attributable to $122.2 million of proceeds from the Revolving Credit Facility, net of costs, partly offset by $70.7 million in repayment of the term loan credit facility, $9.2 million for payment of debt issuance costs, $5.9 million of preferred stock cash dividends and $2.4 million of cash used for share repurchases to satisfy employee tax withholding obligations.
We also incurred $2.0 million of restructuring charges which primarily related to employee termination benefits as a result of our continued cost-reduction efforts during the first half of fiscal 2024. 60 Table of Contents Interest Expense Interest expense primarily consists of interest expense and amortization of debt issuance costs related to our Credit Agreement.
We also incurred $2.0 million of restructuring charges which were primarily related to employee termination benefits as a result of cost-reduction efforts during the first quarter of 2024. 54 Table of Contents Interest Expense Interest expense primarily consists of interest expense and amortization of debt issuance costs related to term loan credit facility with Blue Torch Finance LLC.
(2) The constraints applied to the total estimated lifetime commissions we expect to receive for selling the plan after the carrier approves an application in order to derive the constrained LTV of commissions for approved members recognized for Medicare Advantage, Medicare Supplement and Medicare Part D were 5.5%, 9% and 7%, respectively, for the year ended December 31, 2024 and 7%, 9% and 7%, respectively, for the year ended December 31, 2023. 2024 compared to 2023 – The changes in constrained LTV of commissions per approved member consisted of: • a 4% increase in Medicare Advantage plans, primarily driven by a decrease in constraint due to a decline in volatility and the observed increase in LTV trends as well as an improved ratio of approved members who became paying members, partially offset by less favorable retention trends for 2024 cohorts compared to 2023 cohorts; • a 22% increase in Medicare Supplement plans, primarily due to favorable carrier and contract mix as well as favorable retention; • a 22% decrease in Medicare Part D plans, primarily driven by unfavorable carrier and contract mix, partially offset by improved retention; • a 1% decrease in non-qualified health plans primarily driven by unfavorable retention trends; • a 2% increase in qualified health plans primarily due to favorable carrier and contract mix; • a 7% decrease in short-term health plans primarily due to unfavorable retention as a result of the regulatory change that decreased term limits for short-term health plans; and • a 17%, 14% and 2% increase in dental, vision and small business plans, respectively, primarily driven by favorable carrier and contract mix. 53 Table of Contents Estimated Membership Estimated membership represents the estimated number of members active as of the date indicated based on the number of members for whom we have received or applied a commission payment during the period of estimation as well as the number of approved members during the period of estimation from whom we expect to receive commission payments.
(2) The constraints applied to the total estimated lifetime commissions we expect to receive for selling the plan after the carrier approves an application in order to derive the constrained LTV of commissions for approved members recognized for Medicare Advantage, Medicare Supplement and Medicare Part D were 5.5%, 4.0% and 7.0%, respectively, for the year ended December 31, 2025 and 5.5%, 9.0% and 7.0%, respectively, for the year ended December 31, 2024. 2025 compared to 2024 – The changes in constrained LTV of commissions per approved member primarily consisted of: • a 6% increase in Medicare Advantage plans, primarily driven by more favorable retention assumptions for 2025 cohorts compared to 2024 cohorts and an increase in the ratio of approved members who became paying members, slightly offset by an unfavorable cohort mix; • a 31% increase in Medicare Supplement plans, primarily due to favorable carrier and contract mix, favorable retention assumptions for 2025 cohorts compared to 2024 cohorts and a decrease in the constraint from 9% to 4% due to observed LTV trends; • a 27% increase in Medicare Part D plans, primarily driven by favorable carrier and contract mix; • a 6% decrease in non-qualified health plans primarily driven by unfavorable retention assumptions for 2025 cohorts compared to 2024 cohorts; • a 4% decrease in qualified health plans primarily due to an increase in the constraint from 4% to 10% as a result of observed unfavorable retention trends along with a less favorable carrier and contract mix, partly offset by more favorable retention assumptions for 2025 cohorts compared to 2024 cohorts; • a 26% decrease in short-term health plans primarily due to unfavorable retention assumptions year-over-year, primarily as a result of the regulatory change that decreased term limits for short-term health plans; • a 5% increase in dental plans primarily driven by favorable carrier and contract mix; and 47 Table of Contents • a 9% increase in small business plans primarily driven by favorable cohort mix and carrier and contract mix, partly offset by unfavorable retention assumptions for 2025 cohorts compared to 2024 cohorts.
The estimated grant date fair value of our stock options is determined using the Black-Scholes-Merton pricing model and a single option award approach. The weighted-average expected term for stock options granted is calculated using historical option exercise behavior. The dividend yield is determined by dividing the expected per share dividend during the coming year by the grant date stock price.
The weighted-average expected term for stock options granted is calculated using historical option exercise behavior. The dividend yield is determined by dividing the expected per share dividend during the coming year by the grant date stock price.
As a result, this could affect our effective tax rate and the amount of income tax expense we record, and pay, in future periods. 70 Table of Contents Recent Accounting Pronouncements See Note 1 – Summary of Business and Significant Accounting Policies in our Notes to Consolidated Financial Statements for the recently issued accounting standards that could have an effect on us.
Recent Accounting Pronouncements See Note 1 – Summary of Business and Significant Accounting Policies in our Notes to Consolidated Financial Statements for the recently issued accounting standards that could have an effect on us. 65 Table of Contents
We incur CC&E expenses in assisting applicants during the enrollment process. Variable marketing costs represent costs incurred in member acquisition from our direct marketing and marketing partner channels. Variable marketing costs exclude fixed overhead costs, such as personnel related costs, consulting expenses, and other operating costs allocated to the marketing and advertising department.
We incur CC&E expenses in assisting applicants during the enrollment process. Variable marketing costs represent costs incurred in member acquisition from our direct marketing and marketing partner channels.
Failure to maintain the Minimum Asset Coverage Ratio or the Minimum Liquidity Amount as of the date or the time period required by the H.I.G.
Investment Agreement) of at least 2.5x (the “Minimum Asset Coverage Ratio”) and a Minimum Liquidity Amount (as defined in the H.I.G. Investment Agreement). Failure to maintain the Minimum Asset Coverage Ratio or the Minimum Liquidity Amount as of the date or the time period required by the H.I.G.
During the year ended December 31, 2024, there were no significant changes to our critical accounting policies and estimates. Revenue Recognition and Contract Assets - Commissions Receivable Commission Revenue – Our commission revenue results from approval of a submitted application from health insurance carriers, which we define as our customers under ASC 606.
During the year ended December 31, 2025, there were no significant changes to our critical accounting policies and estimates. Revenue Recognition and Contract Assets - Commissions Receivable Commission Revenue – We earn commission revenue from the sale of insurance policies for which we are the broker of record, when a submitted insurance application is approved by the health insurance carriers.
We estimate commission revenue for each insurance product by 68 Table of Contents using a portfolio approach to a group of approved members by plan type and the effective month of the relevant plan, which we refer to as “cohorts”.
We estimate constrained LTV of commissions for each insurance product by using a portfolio approach to a group of approved members by plan type and the effective month of the relevant plan, which we refer to as “cohorts”. We recognize initial revenue for plans approved during the period by applying the latest estimated constrained LTV of commissions for that product.
The following table shows estimated membership by product as of the periods presented below: As of December 31, 2024 2023 % Change Medicare (1) Medicare Advantage 690,874 622,896 11 % Medicare Supplement 96,894 110,826 (13) % Medicare Part D 210,917 210,876 — % Total Medicare 998,685 944,598 6 % Individual and Family (1) 78,452 86,452 (9) % Ancillary (1) 173,760 180,741 (4) % Small Business (2) 42,899 46,225 (7) % Total Estimated Membership 1,293,796 1,258,016 3 % __________________ (1) To estimate the number of members on Medicare-related, individual and family, and ancillary health insurance plans, we take the respective sum of (i) the number of members for whom we have received or applied a commission payment for a month that may be up to three months prior to the date of estimation (after reducing that number using historical experience for assumed member cancellations over the period being estimated); and (ii) the number of approved members over that period (after reducing that number using historical experience for an assumed number of members who do not accept their approved policy and for estimated member cancellations).
Various circumstances could cause the assumptions and estimates that we make in connection with estimating our membership to be inaccurate, which would cause our membership estimates to be inaccurate. 48 Table of Contents The following table shows estimated membership by product as of the dates presented below: As of December 31, 2025 2024 % Change Medicare (1) Medicare Advantage 691,129 690,874 — % Medicare Supplement 93,913 96,894 (3) % Medicare Part D 177,108 210,917 (16) % Total Medicare 962,150 998,685 (4) % Individual and Family (1) 64,936 78,452 (17) % Ancillary (1) 187,895 173,760 8 % Small Business (2) 35,772 42,899 (17) % Total Estimated Membership 1,250,753 1,293,796 (3) % __________________ (1) To estimate the number of members on Medicare-related, individual and family, and ancillary health insurance plans, we take the respective sum of (i) the number of members for whom we have received or applied a commission payment for a month that may be up to three months prior to the date of estimation (after reducing that number using historical experience for assumed member cancellations over the period being estimated); and (ii) the number of approved members over that period (after reducing that number using historical experience for an assumed number of members who do not accept their approved policy and for estimated member cancellations).
Our CODM considers budget-to-actual variances on a monthly basis for our segment performance measures when making decisions about allocating capital and personnel to our segments. These performance measures include total segment revenue and segment gross profit (loss). Prior to the fourth quarter of 2024, we reported our measure of segment profitability as segment profit (loss).
Our CODM considers budget-to-actual variances on a monthly basis for our segment performance measures when making decisions about allocating capital and personnel to our segments. These performance measures include total segment revenue and segment gross profit (loss). Our business structure is comprised of two operating segments: • Medicare; and • Employer and Individual.
Cash used from changes in net operating assets and liabilities during 2023 primarily consisted of increases of $33.6 million in contract assets – commissions receivable and $1.9 million in prepaid expenses as well as a decrease of $3.4 million in accrued marketing expenses, partially offset by increases of $20.1 million in accrued compensation and benefits.
Cash used from changes in net operating assets and liabilities during 2025 primarily consisted of increases of $123.0 million in contract assets – commissions receivable and $4.7 million in prepaid expenses and a decrease of $2.9 million in accrued compensation and benefits, partially offset by decreases of $9.1 million in accounts receivable and an increase of $5.0 million in accounts payable.
Adjustments for non-cash items primarily consisted of $23.2 million of stock-based compensation expense and $17.4 million of amortization of internally developed software and $2.5 million in depreciation and amortization expense, partially offset by $2.7 million in deferred income taxes.
Adjustments for non-cash items primarily consisted of $18.4 million in deferred income taxes, $15.0 million of stock-based compensation expense and $11.9 million of amortization of internally developed software.
Liquidity and Capital Resources As of December 31, 2024, we had cash, cash equivalents and short-term marketable securities of $82.2 million. During the year ended December 31, 2024, our operating cash outflow was $18.4 million, as summarized below. We have historically financed our operations primarily through cash generated from our operations, equity issuances and debt financing.
During the year ended December 31, 2025, our operating cash outflow was $25.3 million, as summarized below. We have historically financed our operations primarily through cash generated from our operations, equity issuances and debt financing.
Stock-based compensation expense is recognized net of estimated forfeitures. We estimate a forfeiture rate to calculate the stock-based compensation for all of our awards. We evaluate the appropriateness of the forfeiture rate based on historical forfeiture, analysis of employee turnover, and other factors.
We estimate a forfeiture rate to calculate the stock-based compensation for all of our awards. We evaluate the appropriateness of the forfeiture rate based on historical forfeiture, analysis of employee turnover, and other factors. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
We evaluate the appropriateness of our constraints on an annual basis, and we update our assumptions when we observe a sufficient amount of evidence that would suggest that the long-term expectation underlying the assumptions has changed.
We evaluate the appropriateness of our constraints on an annual basis, and we update our assumptions when we observe a sufficient amount of evidence that would suggest that the long-term expectation underlying the assumptions has changed. Additionally, we continuously monitor cash collections and performance for each existing cohort and assess these results in relation to our most recently booked estimates.
Our customer care and enrollment expenses are summarized as follows (dollars in thousands): Change 2024 2023 $ % Customer care and enrollment $ 163,448 $ 149,562 $ 13,886 9 % % of total revenue 31 % 33 % 2024 compared to 2023 – Customer care and enrollment expenses increased by $13.9 million, or 9%, in 2024 compared to 2023.
Our customer care and enrollment expenses are summarized as follows (dollars in thousands): Change 2025 2024 $ % Customer care and enrollment $ 162,885 $ 163,448 $ (563) — % % of total revenue 29 % 31 % 2025 compared to 2024 – Customer care and enrollment expenses decreased by $0.6 million, or roughly flat, in 2025 compared to 2024.
Year Ended December 31, 2023 – Net cash used in operating activities of $6.7 million during 2023 was, primarily driven by a net loss of $28.2 million and changes in net operating assets and liabilities of $19.6 million, partially offset by adjustments for non-cash items of $41.2 million.
Year Ended December 31, 2025 – Net cash used in operating activities of $25.3 million during 2025 was primarily driven by changes in net operating assets and liabilities of $114.9 million, partially offset by adjustments for non-cash items of $49.5 million and net income of $40.0 million.
Employer and Individual Segment 2024 compared to 2023 – Revenue from our E&I segment decreased $14.6 million, or 32%, in 2024 compared to 2023, primarily driven by a $14.2 million decrease in commission revenue as a result of: • lower net adjustment revenue year-over-year, which was $4.1 million in 2024 compared to $14.5 million in 2023; and • a 24%, 9% and 30% decline in individual and family plan, ancillary plan and small business plan approved members, respectively, compared to the same period in 2023.
Employer and Individual Segment 2025 compared to 2024 – Revenue from our E&I segment decreased $9.0 million, or 28%, in 2025 compared to 2024, primarily driven by a $8.3 million decrease in commission revenue primarily as a result of: • lower net adjustment revenue year-over-year, which was $1.4 million in 2025 compared to $4.1 million in 2024; and • a $4.9 million decline in commission revenue from members approved during the period primarily due to a 25% and 35% decline in individual and family plan and short term health plan approved members, respectively, along with lower constrained LTV of commissions for these products, compared to the same period in 2024.
The change was primarily driven by $1.3 million of third-party fees in 2024 as a result of entering into a second amendment of our Credit Agreement and a decrease of $1.2 million in interest income as a result of less favorable short-term investment rates.
The change was primarily driven by a decrease of $3.3 million in interest income as a result of less favorable short-term investment rates and having fewer short-term marketable securities than in 2024.
Availability and Use of Cash We believe our current cash, cash equivalents and short-term marketable securities, including the proceeds from the equity financing we obtained on April 30, 2021 under the H.I.G.
See Note 12 – Debt in our Notes to Consolidated Financial Statements for additional information regarding the term loan credit facility with Blue Torch Finance LLC. Availability and Use of Cash We believe our current cash, cash equivalents and short-term marketable securities, including the proceeds from the equity financing we obtained on April 30, 2021 under the H.I.G.
Our general and administrative expenses are summarized as follows (dollars in thousands): Change 2024 2023 $ % General and administrative $ 89,765 $ 99,363 $ (9,598) (10) % % of total revenue 17 % 22 % 2024 compared to 2023 – General and administrative expenses decreased by $9.6 million, or 10%, in 2024 compared to 2023, primarily due to decreases of $3.3 million in facilities and other operating costs, $2.4 million in personnel related costs due to lower headcount, $2.1 million in professional fees, and $1.9 million in stock-based compensation expense.
Our general and administrative expenses are summarized as follows (dollars in thousands): Change 2025 2024 $ % General and administrative $ 89,555 $ 89,765 $ (210) — % % of total revenue 16 % 17 % 2025 compared to 2024 – General and administrative expenses decreased by $0.2 million, or roughly flat, in 2025 compared to 2024, primarily due to a $3.3 million decrease in stock based compensation expense, a $1.3 million decrease in facilities and other operating expenses and a $0.6 million decrease in other expenses, partly offset by an increase of $5.0 million in personnel and compensation costs, primarily related to higher medical costs and costs associated with our CEO transition.
The majority of our members who terminate their policies do so by discontinuing their premium payments to the carrier or notifying the carrier directly and do not inform us of the cancellation. Also, some of our members pay their premiums less frequently than monthly.
Health insurance carriers bill and collect insurance premiums paid by our members. The majority of our members who terminate their policies do so by discontinuing their premium payments to the carrier or notifying the carrier directly and do not inform us of the cancellation. Therefore, we depend on carriers and others for membership data.
Cost of Revenue Cost of revenue consists of payments related to health insurance plans sold to members who were referred to our website by marketing partners with whom we have revenue-sharing arrangements. In order to enter into a revenue-sharing arrangement, marketing partners must be licensed to sell health insurance in the state where the policy is sold.
Marketing and advertising expenses also include cost of revenue, which consists of payments related to health insurance plans sold to members who were referred to our website by marketing partners with whom we have revenue-sharing arrangements.
(2) Other CC&E costs consist of previously capitalized labor, depreciation and share-based compensation costs. 63 Table of Contents Medicare Segment 2024 compared to 2023 – Revenue from our Medicare segment increased $94.2 million, or 23%, in 2024 compared to 2023, primarily driven by: • a $71.9 million increase in Medicare segment commission revenue due to: ◦ a $59.1 million increase in Medicare Advantage plan commission revenue, driven by 26% growth in Medicare Advantage plan approved members and improved constrained LTV of commissions per approved Medicare Advantage member, ◦ partially offset by lower net adjustment revenue which was $18.7 million in 2024 compared to $33.5 million in 2023. • a $19.8 million increase in Medicare segment fee-based revenue driven by growth in our fee-based BPO arrangements.
(2) Other CC&E costs consist of previously capitalized labor, depreciation and share-based compensation costs. 57 Table of Contents Medicare Segment 2025 compared to 2024 – Revenue from our Medicare segment increased $30.6 million, or 6%, in 2025 compared to 2024, primarily driven by: • a $44.6 million increase in Medicare segment commission revenue due to: ◦ higher net adjustment revenue which was $43.0 million in 2025 compared to $18.7 million in 2024, ◦ a $20.3 million increase in commission revenue from members approved during the period primarily due to improved constrained LTV of commissions per approved member for all Medicare products and a significant increase in hospital indemnity plan approved members, partially offset by a decrease in approved members across all Medicare products. • a $14.0 million decrease in Medicare segment non-commission revenue primarily driven by a decrease in our sponsorship and advertising revenue.
The estimated grant date fair value of market-based performance awards is determined using the Monte-Carlo simulation model and requires the input of subjective assumptions. The estimated fair value for non-market-based performance stock units is estimated on the date of grant based on the current market price of our common shares.
The estimated fair value for non-market-based performance stock units is estimated on the date of grant based on the current market price of our common shares. The estimated grant date fair value of our stock options is determined using the Black- 64 Table of Contents Scholes-Merton pricing model and a single option award approach.
Approved Members Approved members represent the number of individuals on submitted applications, or submissions, which were approved by the relevant insurance carrier for the identified product during the current period. The applications may be submitted in either the current period or prior periods. Not all approved members ultimately become paying members.
The applications may be submitted in either the current period or prior periods. Not all approved members ultimately become paying members.
We often are made aware of policy cancellations and group size changes at the time of annual renewal and update our membership statistics accordingly in the period they are reported. 2024 compared to 2023 – Total estimated membership increased 3% as of December 31, 2024 compared to December 31, 2023 due to: • a 6% increase in Medicare estimated membership year over year, driven by: ◦ an 11% increase in Medicare Advantage plans, primarily due to an increase in Medicare Advantage approved applications, ◦ partially offset by a 13% decrease in Medicare Supplement plans, driven by a decrease in approved members primarily due to the shift of some broker of record arrangements to fee-based arrangement within our Amplify platform, which are not included in estimated membership; • a 9% decline in individual and family plan estimated membership year over year due to a decrease in non-qualified health plan approved applications; • a 4% decline in overall ancillary plan estimated membership year over year, primarily due to a decline in approved applications across several ancillary products; and • a 7% decline in small business plan estimated membership year over year, primarily due to a decrease in approved applications.
We often are made aware of policy cancellations and group size changes at the time of annual renewal and update our membership statistics accordingly in the period they are reported. 2025 compared to 2024 – Total estimated membership declined 3% as of December 31, 2025 compared to December 31, 2024 primarily due to: • a 4% decrease in Medicare estimated membership year over year, driven by: ◦ a 3% and 16% decrease in Medicare Supplement and Medicare Part D plans, respectively, driven by a decrease in approved members, while Medicare Advantage estimated membership remained flat, with new approved members being offset through member switching activity during this past AEP; • a 17% decline in both individual and family plan and small business plan estimated membership year over year due to a decrease in approved applications; and • an 8% increase in overall ancillary plan estimated membership year over year, primarily due to an increase in approved applications for the hospital indemnity plans.
Segment CC&E expenses include expenses we incur in assisting applicants during the enrollment process and exclude operating costs allocated to the CC&E department. 62 Table of Contents Our operating segment revenue and segment gross profit (loss) are summarized as follows (in thousands): Change 2024 2023 $ % Medicare: Total revenue $ 500,638 $ 406,467 $ 94,171 23 % Variable marketing and advertising (157,121) (141,487) (15,634) (11) % Medicare CC&E (150,613) (137,910) (12,703) (9) % Cost of revenue (1,396) (1,312) (84) (6) % Medicare segment gross profit $ 191,508 $ 125,758 $ 65,750 52 % Employer and Individual: Total revenue $ 31,772 $ 46,404 $ (14,632) (32) % Variable marketing and advertising (4,321) (3,304) (1,017) (31) % E&I CC&E (10,103) (9,214) (889) (10) % Cost of revenue (398) (459) 61 13 % E&I segment gross profit $ 16,950 $ 33,427 $ (16,477) (49) % Consolidated: Total revenue $ 532,410 $ 452,871 $ 79,539 18 % Variable marketing and advertising (161,442) (144,791) (16,651) (12) % Segment CC&E (160,716) (147,124) (13,592) (9) % Cost of revenue (1,794) (1,771) (23) (1) % Total segment gross profit $ 208,458 $ 159,185 $ 49,273 31 % A reconciliation of our segment gross profit (loss) to the Consolidated Statements of Comprehensive Income (Loss) for the periods presented is as follows (in thousands): Year Ended December 31, 2024 2023 Total segment gross profit $ 208,458 $ 159,185 Other marketing and advertising (1) (29,395) (27,849) Other CC&E (2) (2,732) (2,438) Technology and content (53,520) (58,609) General and administrative (89,765) (99,363) Impairment, restructuring and other charges (9,475) — Interest expense (11,159) (10,974) Other income, net 6,900 9,453 Income (loss) before income taxes $ 19,312 $ (30,595) _______ (1) Other marketing and advertising costs consist of fixed marketing and advertising, previously capitalized labor, depreciation and share-based compensation costs.
Segment CC&E expenses include expenses we incur in assisting applicants during the enrollment process and exclude operating costs allocated to the CC&E department. 56 Table of Contents Our operating segment revenue and segment gross profit are summarized as follows (in thousands): Change 2025 2024 $ % Medicare: Total revenue $ 531,213 $ 500,638 $ 30,575 6 % Variable marketing and advertising (147,081) (157,121) 10,040 6 % Medicare CC&E (151,092) (150,613) (479) — % Cost of revenue (1,002) (1,396) 394 28 % Medicare segment gross profit $ 232,038 $ 191,508 $ 40,530 21 % Employer and Individual: Total revenue $ 22,795 $ 31,772 $ (8,977) (28) % Variable marketing and advertising (4,356) (4,321) (35) (1) % E&I CC&E (9,378) (10,103) 725 7 % Cost of revenue (331) (398) 67 17 % E&I segment gross profit $ 8,730 $ 16,950 $ (8,220) (48) % Consolidated: Total revenue $ 554,008 $ 532,410 $ 21,598 4 % Variable marketing and advertising (151,437) (161,442) 10,005 6 % Segment CC&E (160,470) (160,716) 246 — % Cost of revenue (1,333) (1,794) 461 26 % Total segment gross profit $ 240,768 $ 208,458 $ 32,310 15 % A reconciliation of our segment gross profit to the Consolidated Statements of Comprehensive Income for the periods presented is as follows (in thousands): Year Ended December 31, 2025 2024 Total segment gross profit $ 240,768 $ 208,458 Other marketing and advertising (1) (28,470) (29,395) Other CC&E (2) (2,415) (2,732) Technology and content (51,829) (53,520) General and administrative (89,555) (89,765) Impairment, restructuring and other charges (2,010) (9,475) Interest expense (10,761) (11,159) Other income, net 2,998 6,900 Income before income taxes $ 58,726 $ 19,312 _______ (1) Other marketing and advertising costs consist of fixed marketing and advertising, previously capitalized labor, depreciation and share-based compensation costs.
On March 13, 2024, the Nominating and Corporate Governance Committee of our Board of Directors approved the appointment of a board observer designated by H.I.G. As of November 30, 2024, we were no longer in compliance with the Minimum Liquidity Amount.
As of September 30, 2023, we failed to maintain the Minimum Asset Coverage Ratio, which entitles H.I.G. to the additional rights set forth above. On March 13, 2024, the Nominating and Corporate Governance Committee of our Board of Directors approved the appointment of a board observer designated by H.I.G.
The H.I.G. Investment Agreement also provides certain redemption rights on or after April 2027. In addition, the Company is required to maintain an Asset Coverage Ratio (as defined in the H.I.G. Investment Agreement) of at least 2.5x (the “Minimum Asset Coverage Ratio”) and a Minimum Liquidity Amount (as defined in the H.I.G. Investment Agreement).
During the year ended December 31, 2025, we paid cash dividends in the aggregate amount of $5.9 million to the holder of our convertible preferred stock. The H.I.G. Investment Agreement also provides certain redemption rights on or after April 2027. In addition, the Company is required to maintain an Asset Coverage Ratio (as defined in the H.I.G.
Since the LTV for any product fluctuates from period to period, the weight given to each product was determined based on their relative LTVs at the time of our adoption of ASC 606. 55 Table of Contents The following table shows the CC&E cost per approved member and variable marketing cost per approved member metrics for the periods presented below: Year Ended December 31, 2024 2023 % Change Medicare Plans: CC&E cost per MA-equivalent approved member (1) $ 349 $ 443 (21) % Variable marketing cost per MA-equivalent approved member (1) 406 449 (10) % Total acquisition cost per MA-equivalent approved member $ 755 $ 892 (15) % IFP Plans: CC&E cost per IFP-equivalent approved member (2) $ 256 $ 179 43 % Variable marketing cost per IFP-equivalent approved member (2) 110 61 80 % Total acquisition cost per IFP-equivalent approved member $ 366 $ 240 53 % _____________ (1) We calculate the number of MA-equivalent approved members by adding the total number of approved Medicare Advantage and Medicare Supplement members and 25% of the total number of approved Medicare Part D members during the periods presented.
The following table shows the CC&E cost per approved member and variable marketing cost per approved member metrics for the periods presented below: Year Ended December 31, 2025 2024 % Change Medicare Plans: CC&E cost per MA-equivalent approved member (1) $ 353 $ 349 1 % Variable marketing cost per MA-equivalent approved member (1) 396 406 (2) % Total acquisition cost per MA-equivalent approved member $ 749 $ 755 (1) % IFP Plans: CC&E cost per IFP-equivalent approved member (2) $ 275 $ 256 7 % Variable marketing cost per IFP-equivalent approved member (2) 141 110 28 % Total acquisition cost per IFP-equivalent approved member $ 416 $ 366 14 % _____________ (1) We calculate the number of MA-equivalent approved members by adding the total number of approved Medicare Advantage and Medicare Supplement members and 25% of the total number of approved Medicare Part D members during the periods presented.
Technology and Content Technology and content expenses consist primarily of compensation and benefits costs for personnel associated with developing and enhancing our website technology as well as maintaining our website.
Technology and Content Technology and content expenses consist primarily of compensation and benefits costs for personnel associated with developing and enhancing our website technology as well as maintaining our website. A portion of our technology and content group is located at our wholly owned subsidiary in China, where technology development costs are generally lower than in the United States.
General and Administrative General and administrative expenses include compensation and benefits costs for personnel working in our executive, finance, investor relations, government affairs, legal, compliance, human resources, facilities and internal information technology departments. These expenses also include fees paid for outside professional services, including audit, tax, legal, government affairs, and information technology fees.
These expenses also include fees paid for outside professional services, including audit, tax, legal, government affairs, and information technology fees.
We estimate the commissions we expect to collect by evaluating various factors, including but not limited to estimating conversion of an approved member to a paying member, forecasting average plan duration and forecasting the commission amounts likely to be received per member.
Our LTVs are based on a number of assumptions, including but not limited to estimating the conversion rate of an approved member to a paying member, forecasting average plan duration, which is the average length of time paying members are active on their plans, and forecasting the commission amounts likely to be received per member.
As of December 31, 2024, the carrying value of the loan under the Credit Agreement was $68.5 million and we were in compliance with our loan covenants. See Note 12 – Debt in our Notes to Consolidated Financial Statements for additional information regarding the Credit Agreement.
See Note 12 – Debt in our Notes to Consolidated Financial Statements for additional information regarding the Revolving Credit Agreement. Term Loan Credit Agreement As discussed above, in connection with the execution of the Revolving Credit Facility, we terminated our $70.0 million secured term loan credit facility with Blue Torch Finance LLC on December 31, 2025.
The following table shows approved members by product for the years presented: Year Ended December 31, 2024 2023 % Change Medicare Medicare Advantage 366,160 290,712 26 % Medicare Supplement 13,822 17,386 (20) % Medicare Part D 27,896 29,378 (5) % Total Medicare 407,878 337,476 21 % Individual and Family 20,671 27,318 (24) % Ancillary 51,556 56,789 (9) % Small Business 5,351 7,613 (30) % Total Approved Members 485,456 429,196 13 % 2024 compared to 2023 – Total approved members grew 13% in 2024 compared to 2023, driven by: • a 21% increase in Medicare approved members driven by: ◦ a 26% increase in Medicare Advantage approved members, due to a 31% increase in Medicare Advantage broker of record submissions primarily as a result of increased consumer demand due to market disruptions during 2024, the strength of our Company rebrand, increased variable marketing spend and an increased number of benefit advisors with improved telesales conversion rates year-over-year, ◦ partially offset by a 20% and 5% decline in Medicare Supplement and Medicare Part D approved members, respectively, primarily caused by the shift of some Medicare Supplement broker of record arrangements to fee-based arrangements within our Amplify platform and a shift away from standalone Medicare Part D plans. • a 24% and 30% decline in individual and family plan and small business health insurance plan approved members, respectively, primarily due to a decrease in volume as we focused on implementing operational enhancements in our E&I segment; and • a 9% decline in ancillary approved members primarily due to declines in dental and short-term approved members. 52 Table of Contents Estimated Constrained Lifetime Value of Commissions Per Approved Member The following table shows our estimated constrained LTV of commissions per approved member by product for the years presented below: Year Ended December 31, 2024 2023 % Change Medicare (1)(2) Medicare Advantage $ 1,088 $ 1,049 4 % Medicare Supplement 1,090 891 22 % Medicare Part D 172 220 (22) % Individual and Family (1) Non-Qualified Health Plans 377 380 (1) % Qualified Health Plans 378 370 2 % Ancillary (1) Short-term 156 167 (7) % Dental 127 109 17 % Vision 83 73 14 % Small Business (1) 235 230 2 % __________ (1) Constrained LTV of commissions per approved member for Medicare, individual and family and ancillary plans represents commissions estimated to be collected over the estimated life of an approved member’s plan after applying constraints in accordance with our revenue recognition policy.
The following table shows approved members by product for the years presented: Year Ended December 31, 2025 2024 % Change Medicare Medicare Advantage 356,831 366,160 (3) % Medicare Supplement 11,606 13,822 (16) % Medicare Part D 10,233 27,896 (63) % Total Medicare 378,670 407,878 (7) % Individual and Family 15,520 20,671 (25) % Ancillary 72,215 51,556 40 % Small Business 5,052 5,351 (6) % Total Approved Members 471,457 485,456 (3) % 2025 compared to 2024 – Total approved members declined 3% in 2025 compared to 2024, driven by: • a 7% decrease in Medicare approved members driven by: ◦ a 3% decrease in Medicare Advantage approved members, due to an 8% decline in Medicare Advantage broker of record submissions as a result of decreased marketing spend in response to the 2025 CMS regulations impacting dual-eligible enrollment rules, as well as an intentional reduction in lower margin marketing channels during the fourth quarter, partially offset by increased consumer demand during the Medicare Advantage OEP in the first quarter of 2025, ◦ a 16% decrease in Medicare Supplement approved members primarily due to the shift—beginning in the second quarter of 2024—of some Medicare Supplement broker of record arrangements to fee-based arrangements within our Amplify platform, which are not reflected as approved members, partially offset by a 39% increase in approved members in the fourth quarter of 2025 compared to the same period last year as a result of efficiencies and improvements made to grow Medicare Supplement during this past AEP, and ◦ a 63% decrease in Medicare Part D approved members primarily driven by regulatory changes that adversely impacted standalone Medicare Part D plan economics and availability, resulting in beneficiaries shifting away from standalone Medicare Part D plans toward Medicare Advantage plans that include prescription drug coverage. • a 25% and 6% decline in individual and family plan and small business health insurance plan approved members, respectively, primarily due to a decrease in volume from shifts in our marketing channel mix and current market conditions, including a decline in qualified health plans from the expiration of the government subsidies; and • a 40% increase in ancillary approved members primarily due to targeted growth in hospital indemnity plans, partially offset by declines in short-term and dental plan approved members. 46 Table of Contents Estimated Constrained Lifetime Value of Commissions Per Approved Member The following table shows our estimated constrained LTV of commissions per approved member by product for the years presented below: Year Ended December 31, 2025 2024 % Change Medicare (1)(2) Medicare Advantage $ 1,154 $ 1,088 6 % Medicare Supplement 1,430 1,090 31 % Medicare Part D 219 172 27 % Individual and Family (1) Non-Qualified Health Plans 354 377 (6) % Qualified Health Plans 363 378 (4) % Ancillary (1) Short-term 115 156 (26) % Dental 133 127 5 % Vision 84 83 1 % Small Business (1) 255 235 9 % __________ (1) Constrained LTV of commissions per approved member for Medicare, individual and family and ancillary plans represents commissions estimated to be collected over the estimated life of an approved member’s plan after applying constraints in accordance with our revenue recognition policy.
Other revenue increased $21.8 million, or 45%, in 2024 compared to 2023. This increase was driven by the expansion of our fee-based BPO arrangements, as well as an increase in sponsorship revenue. Net adjustment revenue consists of increases in revenue for certain prior period cohorts as well as reductions in revenue for certain prior period cohorts.
Other revenue decreased $14.7 million, or 21%, in 2025 compared to 2024, primarily driven by the decrease in sponsorship and advertising revenue. Net adjustment revenue consists of increases and decreases to revenue for certain prior period cohorts.
Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The estimated attainment of performance-based awards and related expense is based on the achievement of certain financial targets over a predetermined performance period, subject to the discretion of the Company's 69 Table of Contents compensation committee.
The estimated attainment of performance-based awards and related expense is based on the achievement of certain financial targets over a predetermined performance period, subject to the discretion of the Company's compensation committee. The estimated grant date fair value of market-based performance awards is determined using the Monte-Carlo simulation model and requires the input of subjective assumptions.
Summary of Selected Metrics We rely upon certain metrics to estimate and recognize commission revenue, evaluate our business performance and facilitate strategic planning.
Additionally, we plan to provide meaningful improvement in our operating cash flows, focus on our direct branded marketing channels to attract higher-margin enrollments and continue our cost savings efforts to preserve our profitability. Summary of Selected Metrics We rely upon certain metrics to estimate and recognize commission revenue, evaluate our business performance and facilitate strategic planning.
Our interest expense is summarized as follows (dollars in thousands): Change 2024 2023 $ % Interest expense $ (11,159) $ (10,974) $ (185) (2) % % of total revenue (2) % (2) % 2024 compared to 2023 – Interest expense increased by $0.2 million, or 2%, primarily driven by higher debt issuance cost amortization as a result of entering into a second amendment of our Credit Agreement and a slight increase in debt interest expense as a result of higher interest rates as compared to 2023.
Our interest expense is summarized as follows (dollars in thousands): Change 2025 2024 $ % Interest expense $ (10,761) $ (11,159) $ 398 4 % % of total revenue (2) % (2) % 2025 compared to 2024 – Interest expense decreased by $0.4 million, or 4%, primarily driven by a $1.0 million decrease in debt interest expense due to lower interest rates as compared to 2024, partly offset by a $0.7 million termination fee paid as a result of the early termination of the term loan credit agreement with Blue Torch Finance LLC during 2025.
Accordingly, prior period amounts have been reclassified to conform to the current period presentation, in all material respects. Our business structure is comprised of two operating segments: • Medicare; and • Employer and Individual. Our CODM does not separately evaluate assets by segment, with the exception of commissions receivable, and therefore assets by segment are not presented.
Our CODM does not separately evaluate assets by segment, with the exception of commissions receivable, and therefore assets by segment are not presented.